CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Dapagliflozin

Last Updated: April 1, 2015
Result type: Reports
Project Number: SR0428-000
Product Line: Common Drug Review

Generic Name: Dapagliflozin

Brand Name: Forxiga

Manufacturer: AstraZeneca Canada Inc.

Indications: Diabetes mellitus (Type 2)

Submission Type: New

Project Status: Complete

Date Recommendation Issued: November 20, 2015

Recommendation Type: List with clinical criteria and/or conditions